Omnicare Clinical Research announced today that it has expanded its global footprint to include an office in Sweden.
OMNICARE CLINICAL RESEARCH OPENS OFFICE IN SWEDEN
King of Prussia, PA-11 August 2008-Omnicare Clinical Research announced today that it has expanded its global footprint to include an office in Sweden. The office is located at Kista Science Tower, Unit B1272, Färögatan 33, 164 51 Kista, Sweden.
“Omnicare Clinical Research continues to expand its worldwide presence through the opening of this new Swedish facility,” said Dr. Dale Evans, President and CEO. “We are committed to the Scandinavian marketplace, where we already have offices in Denmark and Finland. We’re looking forward to future growth and continued success with our partners in the region.”
About Omnicare Clinical Research
Headquartered in King of Prussia, PA, Omnicare Clinical Research provides clinical
development services to pharmaceutical, biotechnology and medical device companies through
its office locations in 31 countries worldwide. As a premier Phase I-IV contract research
organization, Omnicare Clinical Research features diverse therapeutic expertise and a
comprehensive scope of clinical service offerings. Additionally, the company is an industry
leader in geriatrics-focused drug studies. Omnicare Clinical Research focuses on providing clients with a superior drug development experience through strong project management, exceptional service and proactive solutions. The company is a subsidiary of Omnicare, Inc., a leading provider of pharmacy services to long-term care facilities and other chronic care settings comprising nearly 1.4 million beds in 47 states (NYSE: OCR).
www.OmnicareCR.com
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.